Dan Suesskind
Director
Management
Redhill Biopharma
Portugal
Biography
Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind was a member of Teva’s board of directors until recently. Mr. Suesskind also serves as a board member at Migdal Group (one of Israel’s leading insurance and finance groups), Gefen Biomed Investment (TASE: GEFEN), NESS Technologies (NASDAQ: NSTC), Syneron Medical (NASDAQ: ELOS) and the Jerusalem Foundation. He holds a BA in economics and political science from the Hebrew University and an MBA from the University of Massachusetts. Mr. Suesskind is a member of the Israeli Forum of Chief Financial Officers and was awarded the “Life Time Achievement Award” from that forum in 2007.
Research Interest
Gastroenterology
